On November 18, 2025 Eli Lilly and Company (NYSE:LLY) reported it will participate in the Citi’s 2025 Global Healthcare Conference on December 2, 2025. Ilya Yuffa, executive vice president and president Lilly USA and Global Customer Capabilities, will take part in a fireside chat at 10:30 a.m., Eastern time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

(Press release, Eli Lilly, NOV 18, 2025, View Source [SID1234660059])

On November 18, 2025 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, reported that the Company will be presenting three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS ) taking place from December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With three poster presentations, including two potentially high impact late-breaking clinical posters, we will be presenting significant amounts of data to the most prominent breast cancer scientific experts and cancer specialists as we advance our therapies with the goal of developing better clinical outcomes for cancer patients," stated William V. Williams, MD, BriaCell’s President & CEO.

The details of the poster presentations are listed below.

Late-Breaking Abstract Number: 3688
Presentation Number: PS1-13-22
Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM

Late-Breaking Abstract Number: 3713
Presentation Number: PS1-13-23
Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM

Abstract Number: 1614
Presentation Number: PS2-09-03
Presentation Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.
Poster Presentation Date/Time: Wednesday, December 10, 2025, 5:00 PM – 6:30 PM

Following the presentation, copies of the posters will be made available at View Source

(Press release, BriaCell Therapeutics, NOV 18, 2025, View Source [SID1234660841])

On November 18, 2025 Moderna, Inc. (Nasdaq:MRNA), reported its participation in the following upcoming investor conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Piper Sandler’s 37th Annual Healthcare Conference, on Tuesday, December 2nd at 11:00am ET

A live webcast of each of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website.

investors.modernatx.com.

A replay of the webcast will be archived on Moderna’s website for at least 30 days following the presentation.

(Press release, Moderna Therapeutics, NOV 18, 2025, https://feeds.issuerdirect.com/news-release.html?newsid=8786998755631678&symbol=MRNA [SID1234660060])

On November 18, 2025 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), reported the appointment of Kameel D. Farag as its Interim Chief Financial Officer who joined Akari last month. Mr. Farag is a proven biotech and global finance executive with a track record spanning over two decades of scaling innovative biotech companies through transformational growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to welcome Kameel to Akari, who has hit the ground running, at a pivotal time in our company’s growth," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "His deep experience across corporate finance, M&A, and operational build-outs will be instrumental as we accelerate development of our novel ADC platform and advance our lead asset toward the clinic."

Mr. Farag added, "Akari is at the forefront of developing a new class of ADCs designed to disrupt cancer cell survival through RNA splicing modulation. I’m excited to join this talented team and apply my experience to help position Akari for its next phase of growth and value creation."

Mr. Farag joins Akari after having most recently served as Chief Financial Officer and head of business operations at Aspen Neuroscience, where he oversaw tripling the company’s headcount, secured over $150 million in financing, built manufacturing infrastructure, and prepared the company for clinical data and a potential future public offering. Prior to his time at Aspen, Mr. Farag served as SVP Finance at Ionis Pharmaceuticals. As a member of the senior leadership team, he was instrumental in supporting the company’s revenue and profitability growth by building out the finance team, systems and processes to support $1B+ in revenue, multiple marketed products, and a growing wholly-owned pipeline. Earlier in his career, Mr. Farag was with Amgen for more than 16 years, where he held positions of increased leadership, including heading finance for international regions where he focused on driving growth in emerging markets while growing profitability in established markets.

Mr. Farag earned his bachelor’s degree in Business & Economics at University of California, Santa Barbara.

(Press release, Akari Therapeutics, NOV 18, 2025, View Source [SID1234660079])

On November 18, 2025 Biogen Inc. (Nasdaq: BIIB) reported that Alisha Alaimo, President, Head of North America, will participate in a fireside chat during the 8th Annual Evercore Healthcare Conference. The webcast will be live on Tuesday, Dec 2, 2025, at 12:55 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Uptal Patel, Head of Biogen West Coast Hub, will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference. The webcast will be live on Wednesday, Dec 3, 2025, at 11:30 a.m. ET.

To access the live webcasts, please visit the Investors section of Biogen’s website at investors.biogen.com. An archived version of the webcasts will be available for at least 30 days following the presentation.

(Press release, Biogen, NOV 18, 2025, View Source [SID1234660061])